With the investment, B Braun will hold a 20.7% stake in the company, while Trendlines holds a 79.3% stake.
“This agreement with B. Braun further advances our strategic relationship with B. Braun, a relationship now nearly 5 years old. B. Braun was the cornerstone investor in our initial public offering and has invested in several of our portfolio companies. We welcome B. Braun’s investment in Trendlines Medical Singapore as another opportunity to work closely together to develop growth opportunities for innovative medical device technologies in Singapore and the greater Asia-Pacific region,” Trendlines chair & CEO D. Dollinger said in a prepared statement.
B. Braun Asia Pacific prez Anna Braun and Aesculap biz dev director Dr. Boris Hofmann will also join Trendlines Medical Singapore’s board as part of the deal, the companies said.
“Our investment in Trendlines Medical Singapore signifies our commitment to making a significant contribution to medical advancements by promoting the development of new medical products and technologies that meet the challenges in today’s complex health care landscape and allow us to share expertise,” Anna Braun said in prepared remarks.
“The agreement with B. Braun gives further impetus to the launch of Trendlines Medical Singapore. Not just will B. Braun’s investment contribute to the financial strength of the incubator, but B. Braun’s expertise in the medical device field provides an additional layer of know-how for our startup companies, including technology development, support in regulatory, medical and scientific affairs, and marketing and sales,” Trendlines Medical Singapore CEO Eric Loh said in a press release.